Abstract: The system features a user-plotted mood map for deriving a dEMS for a hyper-personalized digital therapeutic comprising a message prescriber; an EMS store; a processor coupled to a memory element stored with instructions, said processor when executing said memory-stored instructions, configure a mood mapping module (mood mapper) to cause display of a coordinate-based sentiment value spectrum (mood map) comprising one positive to negative-scaled axis and one perpendicular active to passive scaled axis forming a two-dimensional plot of a sentiment value along a positive to negative line (positivity correlate) and an active to passive line (activity correlate); at least one user-plotted point on the displayed mood map to reflect a two-dimensional EMS (dynamic EMS) along the two correlates of positivity and activity, said dynamic EMS indicating a granular assessment of at least one of a feeling, sensation, mood, mental state, emotional condition, or physical status of the user; and the message prescriber deliveri

Abstract: Disclosed herein is a system and method for delivering a digital therapeutic, specific to a user emotional or mental state (EMS). This entails recognizing at least one EMS selected by the user from a plurality of EMS, said selected EMS indicating at least one of a feeling, sensation, type of discomfort, mood, mental state, emotional condition, or physical status of the user. Pushing at least a primary-level message personalized to the user based on at least one stored message coupled to the selected EMS; wherein the at least primary-level messages contain at least one of a text, image, sound, video, art asset, suggested action or recommended behavior. The actions suggested or behaviors recommended are supported by at least one independent source of peer-reviewed research, as verified by a credentialed EMS expert.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Abstract: The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of complementary reactivity on the other species of the conjugate. Also provided are methods of using the compounds of the invention to detect and/or quantify an analyte in a sample. In an exemplary embodiment, the invention provides multi-color assays incorporating the compounds of the invention.

Abstract: The invention describes novel preparations and their use for reducing the acute damaging effect of ammonia in organisms living in the keeping water of aquariums, garden ponds, or aquaculture systems. The preparations consist of adducts of sodium hydrogen sulfite at an aliphatic aldehyde of the general formula X—(CH2)n—CO—H, wherein n means the numbers 0 to 3, and X means an —OH, —COOH, or —CO—H group, wherein X cannot be —OH, if n=0. The preparations are used in the keeping water with a concentration of 10 to 140 mg/l.

Abstract: Multivitamin/Multimineral supplements are provided for supplementing iron and desirable nutrients in the diet of mammals. The supplements include an iron-amino acid chelate, a form of iron more bioavailable than traditional iron salts. The supplements may further include a pharmaceutically accepted salt form of iron as well as other nutritional vitamins and minerals. The supplements are useful for providing iron for pregnant and lactating females as well as for persons suffering from anemia.

Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.

Abstract: Analogs related to oleamide are employed for potentiating the 5-HT2A and 5-HT1A responses to serotonin (5-HT). With respect to the potentiation of the 5-HT2A receptor response, it is disclosed that, of the naturally occurring fatty acids, the primary amide of oleic acid (oleamide) is the most effective potentiating agent of serotonin and that the potentiating activity of oleamide analogs is highly dependent upon their structural features. In particular, the presence, position, and stereochemistry of the 9-cis double bond is required and even subtle structural variations reduce or eliminate activity. Secondary or tertiary amides may replace the primary amide but follow a well-defined relationship requiring small amide substituents suggesting that the carboxamide serves as a hydrogen bond acceptor but not donor. Alternative modifications at the carboxamide as well as modifications of the methyl terminus or the hydrocarbon region spanning the carboxamide and double bond typically eliminate activity.

Abstract: The present invention describes a novel treatment for neuropsychiatric disorders, including anxiety disorders, mood disorders, psychotic disorders, somatoform disorders, and neuropsychiatric symptoms resulting from movement disorders. The treatment of the present invention utilizes any agent that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate (calcium N-acetylhomotaurinate). Alternatively, separate agents having these activities can be combined as a compound or mixture and thereby administered together. The invention also provides for a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker, that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium.

Abstract: The present invention describes a novel treatment for neuropsychiatric disorders, including anxiety disorders, mood disorders, psychotic disorders, somatoform disorders, and neuropsychiatric symptoms resulting from movement disorders. The treatment of the present invention utilizes any agent that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate (calcium N-acetylhomotaurinate). Alternatively, separate agents having these activities can be combined as a compound or mixture and thereby administered together. The invention also provides for a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker, that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium.

Abstract: Oleamide is an endogenous fatty acid primary amide that possesses sleep-inducing properties in animals and has been shown to effect seratonergic systems and block gap junction communication in a structurally specific manner. Certain agents can serve both as an oleamide agonist and as an inhibitor of fatty acid amide hydrolase. Fatty acid amide hydrolase is responsible for the rapid inactivation of oleamide in vivo. The structural features of oleamide required for inhibition of gap junction-mediated chemical and electrical transmission in rat glial cells are defined. Effective inhibitors fall into two classes of fatty acid primary amides of which oleamide and arachidonamide are the prototypical members. Of these two, oleamide constitutes the most effective and its structural requirements for inhibition of the gap junction are well defined.

Abstract: Use of at least one aminothiol ester derivative for the preparation of a pharmaceutical composition intended to increase the inhibition of a character resistant to the induction of apoptosis of transformed cells, this character being due to the bc12 gene present in these cells. The pharmaceutical composition is more particularly intended to treat pathologies chosen from breast cancers, B cell lymphomas, leukaemias, neuroblastomas, adenocarcinomas of the prostate, prolactinomas and other pituitary adenomas.

Abstract: A method for the preparation of Mycobacteria from any liquid, semi solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.

Abstract: Methods are provided to prepare a variety of tissues in a pathology-stable form keyed to the use of an aqueous solution of C.sub.2-6 dialdehyde and/or dialdehyde addition products, including the group consisting of glyoxal and/or glutaraldehyde in an amount sufficient to prevent autolysis and other degradative changes in various tissues. The said solution is capable of treating a tissue so as to maintain the tissue in a condition suitable for pathology and/or other experimental observation. The stabilizing solution is also useful to prepare parts or whole animals and plants in an anatomically preserved state for a prolonged period of time, and compositions useful in that method.

Abstract: Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of sarcoidosis.

Abstract: Cosmetic and/or dermatological compositions containing a non-photocatalytic metal oxide and tocopherol and, optionally, a metal-inactivating complexing agent are effective for inhibiting the light-induced peroxidation of lipids, and in particular lipids of sebaceous origin such as squalene.

Abstract: Apoptosis (programmed cell death) in mammalian organisms is modulated, whether initiated or suppressed, for example for preventing and/or combating photoinduced or chronologic aging of the skin or for treating a wide variety of human afflictions, by administering thereto, for such prolonged period of time as is required to elicit the desired response, an effective apoptosis-modulating amount of at least one active species selected from among methional, malondialdehyde, or factor influencing the intracellular concentration of methional or malondialdehyde.

Abstract: The present invention provides a method for providing nutrition to elderly patients. Pursuant to the present invention, the enteral composition includes a protein source, a lipid source, and a carbohydrate source. Preferably, the protein source includes at least 18% of the total calories. In an embodiment, the carbohydrate source includes a source of dietary fiber including a balance of soluble to insoluble fiber ratio of approximately 1:3. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.

Abstract: The present invention provides a method for providing nutrition to non-catabolic and moderately catabolic patients. Pursuant to the present invention, the enteral composition includes a peptide based protein source of hydrolyzed whey, a lipid source, and a carbohydrate source. Preferably, the protein source includes approximately 22% to about 27% of the total calories. The composition has a caloric density of approximately 1000 Kcal/L and a low osmolality of approximately 300 to 450 mOsm/Kg H.sub.2 O. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.

Abstract: A method for the preparation of Mycobacteria from any liquid, semi-solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.

Abstract: A nutritional supplement and a method of use therefor in equine are disclosed. The equine nutritional supplement alleviates various chronic or acute conditions in equine associated with hormonal imbalances. The equine nutritional supplement contains a lecithin, B vitamins, antioxidants such as vitamin E and/or selenium, and lipotropic agents such as inositol and/or methionine. The lecithin acts as a source of phospholipids and choline to improve and maintain body cell integrity. The equine nutritional supplement is particularly useful in extending the age of reproductive capability in equine.

Abstract: The present invention provides a method for providing nutrition to elderly patients. Pursuant to the present invention, the enteral composition includes a protein source, a lipid source, and a carbohydrate source. Preferably, the protein source includes at least 18% of the total calories. In an embodiment, the carbohydrate source includes a source of dietary fiber including a balance of soluble to insoluble fiber ratio of approximately 1:3. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.

Abstract: A pour-on formulation containing a therapeutically effective amount of a trace element chosen from the group comprising selenium, copper, cobalt and iodine, in an aqueous or non-aqueous carrier. A non-aqueous formulation contains selenium dioxide dissolved in butyl dioxitol. An aqueous pour-on contains selenium selenate with keltrol, a wetting agent and water.

Abstract: Alkene aldehyde sulfoxylates are more effective than their saturated aldehyde sulfoxylate counterparts as systemic pesticides for protecting plants.

Abstract: An alkali-metal dithionite is readily transformed into an aldehyde sulfoxylate microbicide which is absorbed through plant leaves and is more stable against oxidation.

Abstract: A method for treating and curing the viral disease of Herpes simplex is presented wherein a chemical composition comprising a saturated dialdehyde containing 2-6 carbon atoms, a lower alkanol and an alkalinating agent is applied directly to the erupted or broken blister or applied directly to the resulting ulcer at its initial stage of development.

Abstract: The present invention provides a method for providing nutrition to elderly patients. Pursuant to the present invention, the enteral composition includes a protein source, a lipid source, and a carbohydrate source. Preferably, the protein source includes at least 18% of the total calories. In an embodiment, the carbohydrate source includes a source of dietary fiber including a balance of soluble to insoluble fiber ratio of approximately 1:3. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.

Abstract: The present invention provides a method for providing nutrition to elderly patients. Pursuant to the present invention, the enteral composition includes a protein source, a lipid source, and a carbohydrate source. Preferably, the protein source includes at least 18% of the total calories. In an embodiment, the carbohydrate source includes a source of dietary fiber including a balance of soluble to insoluble fiber ratio of approximately 1:3. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.